CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 267 enrolled
Drug / intervention
mRNA-4157 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03897881
NCT03897881Phase 2Active
CompareCT.gov

A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)

ModernaTX, Inc.·interventional·Posted Apr 1, 2019·Updated Dec 3, 2025

In Brief

A Phase 2 clinical trial evaluating mRNA-4157 and Pembrolizumab for Melanoma. Active but no longer recruiting, targeting 267 participants across 23 sites in 2 countries.

Detailed Summary

The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesAustralia, United States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2Active
201920202021202220232024202520262027202820292030203120322033
First PostedApr 1, 2019
Enrollment StartJul 18, 2019
Primary CompletionNov 30, 2032
TodayJul 2, 2026
Enrollment to primary: 13.4 yearsPosted 7.3 years agoPrimary completion in 6.4 years

Interventions

mRNA-4157drug

Individualized Neoantigen Therapy

Pembrolizumabbiological

Intravenous infusion